Cath Trigwell

Feedback Suppression of PI3Kα Signaling in PTEN-Mutated Tumors Is Relieved by Selective Inhibition of PI3Kβ

Sarit Schwartz, John Wongvipat, Cath Trigwell et al. · Cancer Cell · 2014 · 261 citations · Full text

Signal Transduction, Signaling Pathway, Cell Regulation +12

AZD8931, an Equipotent, Reversible Inhibitor of Signaling by Epidermal Growth Factor Receptor, ERBB2 (HER2), and ERBB3: A Unique Agent for Simultaneous ERBB Receptor Blockade in Cancer

D. Mark Hickinson, Teresa Klinowska, Georgina Speake et al. · Clinical Cancer Research · 2010 · 118 citations

Inhibition of PI3Kβ Signaling with AZD8186 Inhibits Growth of PTEN-Deficient Breast and Prostate Tumors Alone and in Combination with Docetaxel

Urs J. Hancox, Sabina Cosulich, Lyndsey Hanson et al. · Molecular Cancer Therapeutics · 2014 · 99 citations · Full text

Intermittent High-Dose Scheduling of AZD8835, a Novel Selective Inhibitor of PI3Kα and PI3Kδ, Demonstrates Treatment Strategies for <i>PIK3CA</i> -Dependent Breast Cancers

Kevin Hudson, Urs J. Hancox, Cath Trigwell et al. · Molecular Cancer Therapeutics · 2016 · 42 citations · Full text

Discovery of AZD8931, an Equipotent, Reversible Inhibitor of Signaling by EGFR, HER2, and HER3 Receptors

Bernard Barlaam, Judith Anderton, Peter Ballard et al. · ACS Medicinal Chemistry Letters · 2013 · 36 citations · Full text

Her3 Receptors, Molecular Biology, Tumor Biology +18